Your AI-Trained Oncology Knowledge Connection!
Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, comment on the role of TACE (transarterial chemoembolization) in early line settings for the management of BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma and whether systemic therapy has the potential to replace TACE.
Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, review the REFLECT trial and discuss the use of lenvatinib in patients with BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma.
Assessing outcomes associated with systemic therapy, such as lenvatinib and sorafenib, for patients with BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma based on data from the IMbrave150 and GIDEON trials.
Practical considerations for TACE (transarterial chemoembolization) in unresectable BCLC stage B HCC, including assessing radiologic response and determining when to initiate systemic therapy.
Examining individual patient assessment for using TACE (transarterial chemoembolization) in unresectable BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma and the health care team involved.
Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, discuss the benefit/risk ratio of first-line locoregional therapies in advanced hepatocellular carcinoma.
Amit Singal, MD, MS, reviews challenges in the management of advanced hepatocellular carcinoma (HCC).
